Tofacitinib (citrate) [540737-29-9]

Catalog number: HY-40354A_10mM
Brand: MedChem Express
Packing: 10 mM
Other sizes: Other sizes available
Price: € 109.00
Expected delivery time: 10 days

Product specifications for - Tofacitinib (citrate) [540737-29-9]

Product group: Chemicals
Category: Other
CAS No.: 540737-29-9
Purity: >98%
Molecular Formula: C22H28N6O8
Molecular weight: 504.49
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. IC50 value: 1 nM [1] Target: JAK3 in vitro: CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2-induced proliferation with 30-fold greater potency than its effects on GM-CSF-induced proliferation [1]. CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM) [2]. CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells [3]. in vivo: In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be 60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively) [1]. Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87-30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10-30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day) [2].
Safety information: 
Additional information: 
Synonyms: HY-40354A
Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Read more
Sci Rep. 2021 Apr 1;11(1):7372. Read more
Pulm Pharmacol Ther. 2017 Apr;43:60-67. Read more
PLoS One. 2018 Jan 10;13(1):e0189247. Read more
Phytother Res. 2021 Feb;35(2):1033-1047. Read more
Mol Hum Reprod. 2021 Mar 24;27(4):gaab016. Read more
J Pharmacol Exp Ther. 2019 Aug;370(2):137-147. Read more
J Med Chem. 2021 Feb 11. Read more
J Immunol. 2013 Oct 1;191(7):3568-77. Read more
J Biochem Mol Toxicol. 2021 Jul 31;e22851. Read more